Abstracts tagged "immunology"

Abstract Number: 1339 • ACR Convergence 2025
Inflammatory Rheumatic Diseases in IDH-mutated Myeloid Neoplasms: Clinical Spectrum and Response to IDH Inhibitors
Romain Stammler¹, Peter Chen², Orianne Debeaupuis², Lin Pierre Zhao¹, Mirabelle Ruyer Thompson¹, Eve Zakine¹, Julien Rossignol¹, Lauriane Goldwirt¹, Thibault Comont³, Mael Heiblig⁴, Lionel Ades¹, Marie Sebert¹, Jean-sébastien Allain⁵, Julien Campagne⁶, Marie Anne Couturier⁷, Marina Cumin⁸, Marie Caroline Dalmas⁹, Guillaume Denis¹⁰, Cecile Devloo¹¹, Adrien De Voeght¹², Louis Drevon¹, Pierre Duffau¹³, Sophie georgin-Lavialle¹⁴, Delphine Gobert¹, Noemie Abisror¹⁵, Olivier Kosmider¹⁶, Fréderic Rieux-Laucat², Estibaliz LAZARO¹⁷, Jean Guillaume Lopez¹⁸, Alexandre Maria¹⁹, Wladimir Mauhin²⁰, Julie Merindol²¹, Claire Merlot²², Tristan Mirault¹, Laurent Pascal²³, François Perrin²⁴, Emmanuel Raffoux¹, Ramy Rahme²⁵, Damien Roos-Weil¹, Benjamin Terrier²⁶, Benjamin Torreau²⁷, Olivier Fain¹, Pierre Fenaux¹, Pierre Hirsch¹, Vincent Jachiet¹, Jerome Hadjadj¹ and Arsène Mekinian²⁸, ¹Assistance Publique des Hôpitaux de Paris, Paris, France, ²Imagine Institute, Paris, France, ³Centre Hospitalier Universitaire Toulouse Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France, ⁴Lyon-Sud Hospital, Hospices Civils de Lyon, Paris and Université Claude Bernard, Lyon, France, ⁵Scorff-Lorient Hospital, Lorient, France, ⁶Hospital Robert Schuman, Metz, France, ⁷Centre Hospitalier Régional et Universitaire de Brest, Brest, France, ⁸Centre hospitalier de Libourne, Libourne, France, ⁹Strasbourg University Hospital Center, Strasbourg, France, ¹⁰Centre Hospitalier Rochefort, Rochefort, France, ¹¹Centre hospitalier de Dieppe, Dieppe, France, ¹²CHU of Liège, Liège, Belgium, ¹³Groupe Hospitalier Saint-André, Bordeaux, France, ¹⁴Sorbonne university, Tenon hospital, DMU³ID, CEREMAIA, ERN RITA, Paris, France, ¹⁵Internal Medicine, CHU Saint-Antoine,, Paris, France, ¹⁶AP-HP, Hopital Cochin, Institut Cochin, CNRS UMR⁸¹⁰⁴, INSERM U¹⁰¹⁶ Université Paris Cité Paris France., PARIS, France, ¹⁷Bordeaux University Hospital, Pessac, France, ¹⁸Dupuytren University Hospital, Limoges, France, ¹⁹Saint-Eloi Hospital, Montpellier, France, ²⁰Croix Saint Simon Hospital, Paris, France, ²¹University Hospital of Nice, Nice, France, ²²Centre hospitaliser d’Orléans, Orléans, France, ²³Hôpital Saint-Vincent de Paul, Lille, France, ²⁴Centre Hospitalier de Saint-Nazaire, Saint Nazaire, France, ²⁵Assistance Publique des Hôpitaux de Paris, Bobigny, France, ²⁶Cochin Hospital, Paris, France, ²⁷Internal Medicine and Immunology, CHU Tours, Tours, France, ²⁸Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France
Background/Purpose: Clonal hematopoiesis has emerged as a key contributor to systemic inflammation, bridging hematologic and immune-mediated inflammatory disorders (IMIDs). Isocitrate dehydrogenase 1 and 2 (IDH1/2)…
Abstract Number: 1004 • ACR Convergence 2025
Single-Cell Analysis Reveals Tissue Resident Memory T Cells Heterogeneity in the Joint
Yang Yang¹, Yusuke Miyashita², Madison Mangin³, Kellen Winden¹, Peter Nigrovic² and Margaret Chang¹, ¹Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Brookline, MA, ³Boston Children's Hospital, St Simons Island, GA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint-specific memory, the phenomenon in which arthritis repeatedly flares in the same joints. We…
Abstract Number: 0899 • ACR Convergence 2025
Altered B cell Subsets Shared in Immune Checkpoint Inhibitor Associated Sicca Syndrome and Sjogren’s Disease
Caroline Atlas¹, Balakrishnan Kamaraj¹, Omid Jamshidi¹, Adam Mor¹, Yevgeniya Gartshteyn², Teja Kapoor³ and Robert Winchester¹, ¹Columbia University, New York, NY, ²Columbia University Medical Center, Glen Rock, NJ, ³Columbia University Irving Medical Center, New York, NY
Background/Purpose: Sicca symptoms may develop in the setting of immune checkpoint inhibitor (ICI) therapy and are clinically indistinguishable from those encountered in Sjogren’s disease (SjD).…
Abstract Number: 0781 • ACR Convergence 2025
Comprehensive mass cytometry analyses of disease-related cells in adult-onset Still’s disease
Hiroto Yoshida¹, Mayu Magi¹, Hiroya Tamai², Kotaro Matsumoto², Keiko Yoshimoto², Tetsuhiro Soeda¹ and Yuko Kaneko², ¹Chugai Pharmaceutical Co., Ltd. Product Research Dept., Yokohama, Kanagawa, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan
Background/Purpose: Adult-onset Still's Disease (AOSD) is a rare autoinflammatory disorder characterized by high fever, rash, and arthritis. Although overactivation of macrophages, an increase in specific…
Abstract Number: 0008 • ACR Convergence 2025
Characterization of S-1117, a novel pan-IgG protease engineered for reduced immunogenicity using the IMPACT platform
Julia Manasson¹, Liliana Sanmarco², Alex Pellerin², Maria Cecilia Ramello², Agustin Plasencia², Jordan Anderson², Tobias Green², Andita Newton², Ryan Peckner², Yi Xing², Heather Vital³, Nathan Higginson-Scott², John Sundy⁴, Kevin L. Otipoby² and Ivan Mascanfroni², ¹Seismic Therapeutic, New York, NY, ²Seismic Therapeutic, Watertown, MA, ³Seismic Therapeutic, Lexington, MA, ⁴Seismic Therapeutic, Durham, NC
Background/Purpose: Pathogenic autoantibodies are key effectors of inflammation, promoting tissue damage in autoantibody-mediated diseases such as inflammatory myopathies, lupus nephritis, Sjogren’s syndrome, antiphospholipid syndrome, and…
Abstract Number: 2665 • ACR Convergence 2025
Preexisting Antibodies Against Vaccine Antigens Are Preserved In Patients With Systemic Lupus Erythematosus and Sjögren’s Disease Upon Ianalumab Treatment While Autoantibodies Decline
Thomas Dörner¹, Nan Shen², Thomas Grader-Beck³, Caroline Walter⁴, Catherine Wioland⁴, Celine Rauld⁴, Patrick Schmutz⁴, Simone Riek⁴, Wolfgang Hueber⁵, CAROLE SIPS⁶, Stephen Oliver⁴, Carol Lau⁷, Claire Bonal⁶ and Isabelle Isnardi⁸, ¹Charite Universitétsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany, ²Shanghai Jiang Tong University School of Medicine, Shanghai, China (People's Republic), ³Johns Hopkins, Reisterstown, MD, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharmaceuticals, Basel, Switzerland, ⁶Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, ⁸Novartis, Gueberschwihr, France
Background/Purpose: Ianalumab, an afucosylated mAb, depletes B cells via enhanced antibody (Ab)-dependent cellular cytotoxicity and blocks B cell-activating factor (BAFF): BAFF-receptor (BAFF-R) mediated signals.1 It…
Abstract Number: 2168 • ACR Convergence 2025
Training Objective Structured Clinical Examinations in a Clinical Immunology department: Expectations and Perceptions of Medical students at Graduating Level
Aïcha Kante¹, Damien Sène², Venceslas Bourdin³, Dikélélé Elessa³, William Bigot³, Valentine Pagis³, Frédéric Truffinet³, Stéphane Mouly³ and Cloé Comarmond¹, ¹Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U⁹⁴², Paris, France, ²Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, Ile-de-France, France, ³Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, France
Background/Purpose: Objective Structured Clinical Examinations (OSCEs) are based on various starting clinical scenarios conducted in a simulated environment that allow for the standardized assessment of…
Abstract Number: 1755 • ACR Convergence 2025
Multi-Omic Profiling Of CD8+ T Cells In Axial Spondyloarthritis (axSpA) And Reactive Arthritis (ReA) Implicates Common Pathways
Zoya Qaiyum¹, Michael Tang², Shirin Soleimani³, Addison Pacheco², Melissa Lim⁴, Fataneh Tavasolian⁴, Trevor Pugh³ and Robert Inman², ¹Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: The strong clinical and genetic associations between axial spondyloarthritis (axSpA) and inflammatory bowel disease (IBD) underscore the pathogenic role of the gut-joint axis. We…
Abstract Number: 1314 • ACR Convergence 2025
Protein-Specific Anti-Malondialdehyde-Acetaldehyde Antibodies and Cardiovascular Disease Outcomes in Rheumatoid Arthritis
Julia King¹, Michael Duryee¹, Punyasha Roul², Katherine Wysham³, Grant Cannon⁴, Gary Kunkel⁵, John Richards⁶, Isaac Smith⁷, Beth Wallace⁸, Gail Kerr⁹, Andreas Reimold¹⁰, Pascale Schwab¹¹, Daniel Anderson¹², Wenxian Zhou¹³, Joshua Baker¹⁴, Ted Mikuls¹, Bryant England¹ and Tate Johnson¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ⁷Duke University Hospital, Durham, NC, ⁸Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁹Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹⁰Dallas VA Medical Center, Dallas, TX, ¹¹VA Portland and Oregon Health & Science University, Portland, OR, ^120587964, Durham, NC, ¹³University of Nebraska Medical Center, Bellevue, NE, ¹⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cardiovascular disease (CVD) remains the leading cause of death in rheumatoid arthritis (RA), driven primarily by atherosclerotic CVD (ASCVD) and heart failure (HF). Malondialdehyde-acetaldehyde…
Abstract Number: 1003 • ACR Convergence 2025
Potent Engineering of Polyfunctional CD8+ T Cells by a Novel In Vivo CAR mRNA Product Candidate (CPTX2309) in a Targeted Lipid Nanoparticle (tLNP) Utilizing CellSeekerTM Technology
Yan Zhang¹, Brittany Ross¹, Aditi Upadhye¹, Diana Galvan¹, Shaun E Grosskurth¹, Yanjie Bao¹, Romina Riener¹, Annabel Wang¹, Aric Frantz¹, Gregor B Adams¹, Michael Rosenzweig¹, Ramin Farzaneh-Far¹, Priya Karmali¹, Adrian I Bot¹, Carl June² and Haig Aghajanian¹, ¹Capstan Therapeutics, San Diego, CA, ²University of Pennsylvania, Philadelphia, PA
Background/Purpose: A major objective in autoimmunity is immune reset, requiring autoreactive B cell depletion in tissues. We designed an in vivo CAR product candidate (CPTX2309)…
Abstract Number: 0898 • ACR Convergence 2025
Distinct B Cell and Plasma Cell Immunosuppression Strategies Eliminate Antigen-Specific Cells of the B Lineage
Carley Tasker¹, Nicholas Giovannone², Nyanza Rothman², Sofia Caruso², Julia Provino², Laura Johnsen², Johanna Napetschnig², Jamie Orengo¹, Christos Kyratsous², Andre Limnander¹, Katherine Cygnar² and Andrew Baik², ¹Regeneron, Tarrytown, NY, ²Regeneron Pharmaceuticals, Tarrytown
Background/Purpose: Development of effective targeting strategies to eliminate sources of antibody production presents utility in the treatment of autoimmune diseases driven by pathogenic autoantibodies. Furthermore,…
Abstract Number: 0747 • ACR Convergence 2025
Patterns of Macrophage Polarization Induced by Serum from Patients with Giant Cell Arteritis and Takayasu’s Arteritis
Irene Carrión-Barberà¹, Ryan D. Stultz², David Cuthbertson³, Nader Khalidi⁴, Curry Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Kenneth Warrington¹², Peter Merkel⁷ and Christian Lood¹³, ¹Department of Rheumatology. Hospital del Mar, Barcelona, Spain, ²University of Washington, Division of Rheumatology, Seattle, WA, ³University of South Florida, Tampa, ⁴Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Pennsylvania, Philadelphia, PA, ⁸VA Boston Healthcare System, Boston, MA, ⁹University of Colorado, Denver, CO, ¹⁰Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, ROCHESTER, MN, ¹³University of Washington, Division of Rheumatology, Seattle
Background/Purpose: Macrophages play a central role in the pathogenesis of large-vessel vasculitides, including giant cell arteritis (GCA) and Takayasu’s arteritis (TAK). Characterizing patterns of macrophage…
Abstract Number: L11 • ACR Convergence 2024
Rheumatology Diagnostics Utilizing Artificial Intelligence (ANA Reader©) for ANA Pattern Identification and Titer Quantification
May Choi¹, Farbod Moghaddam¹, Mohammad Sajadi¹, Ann E. Clarke¹, Sasha Bernatsky², Karen Costenbader³, Irene Chen⁴, Murray Urowitz⁵, John Hanly⁶, Caroline Gordon⁷, Sang-Cheol Bae⁸, Juanita Romero-Diaz⁹, Jorge Sanchez-Guerrero¹⁰, Daniel Wallace¹¹, David Isenberg¹², Anisur Rahman¹³, Joan Merrill¹⁴, Paul Fortin¹⁵, Dafna Gladman¹⁶, Ian Bruce¹⁷, Michelle Petri¹⁸, Ellen Ginzler¹⁹, Mary Anne Dooley²⁰, Rosalind Ramsey-Goldman²¹, Susan Manzi²², Andreas Jönsen²³, Graciela Alarcón²⁴, Ronald Van Vollenhoven²⁵, Cynthia Aranow²⁶, Meggan Mackay²⁶, Guillermo Ruiz-Irastorza²⁷, S. Sam Lim²⁸, Murat Inanç²⁹, Kenneth Kalunian³⁰, Soren Jacobsen³¹, Christine Peschken³², Diane Kamen³³, Anca Askanase³⁴, Marvin Fritzler³⁵ and Mina Aminghafari¹, ¹University of Calgary, Calgary, AB, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Brigham and Women's Hospital/Harvard Medical School, Boston, MA, ⁴UC Berkeley and UCSF, Berkeley, CA, ⁵Self employed, Toronto, ON, Canada, ⁶Dalhousie University, Halifax, NS, Canada, ⁷University of Birmingham, Birmingham, United Kingdom, ⁸Hanyang University Medical Center, Seoul, South Korea, ⁹The National Institute of Medical Sciences and Nutrition, Mexico City, Mexico, ¹⁰Krembil Research Institute, Toronto, ON, Canada, ¹¹Cedars Sinai Medical Center, Studio City, CA, ¹²Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine, University College London, London, United Kingdom, ¹³University College London, London, United Kingdom, ¹⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Centre ARThrite - CHU de Québec - UniversitéLaval, Quebec, QC, Canada, ¹⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁷Queen's University Belfast, Belfast, United Kingdom, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹SUNY Downstate Health Sciences University, New York, NY, ²⁰UNC physician network, Chapel Hill, NC, ²¹Northwestern University, Chicago, IL, ²²Allegheny Health Network, Pittsburgh, PA, ²³Lund University, Lund, Sweden, ²⁴The University of Alabama at Birmingham, Oakland, CA, ²⁵Amsterdam UMC, Amsterdam, Netherlands, ²⁶Feinstein Institutes for Medical Research, New York, NY, ²⁷Biobizkaia Health Research Institute, Bilbao, Spain, ²⁸Emory University, Atlanta, GA, ²⁹Istanbul University, Istanbul, Turkey, ³⁰UC San Diego, La Jolla, CA, ³¹Rigshospitalet, Copenhagen, Denmark, ³²University of Manitoba, Winnipeg, MB, Canada, ³³Medical University of South Carolina, Johns Island, SC, ³⁴Columbia University Medical Center, New York, NY, ³⁵Mitogen Diagnostics Corp, Calgary, AB, Canada
Background/Purpose: Antinuclear antibody (ANA) immunofluorescence (IFA) patterns and titers are a key part of rheumatology diagnostics, however, there is considerable intra- and inter-laboratory variability with…
Abstract Number: 0240 • ACR Convergence 2024
Cellular and Humoral Responses Following a Fifth, Updated SARS-CoV-2 Vaccine Dose and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study
Hilde S. Ørbo¹, Asia-Sophia Wolf², Taissa M. Kasahara³, Kristin H. Bjørlykke⁴, Ingrid Jyssum⁵, Joseph Sexton⁵, Anne Therese Tveter⁵, Guri Solum², Ingrid Fadum Kjønstad², Ingrid E. Christensen⁵, Tore K. Kvien⁶, Jørgen Jahnsen⁷, Espen A. Haavardsholm¹, Ludvig A. Munthe⁸, Sella A. Provan⁵, John Torgils Vaage⁸, Kristin K. Jørgensen⁴, Gunnveig Grødeland⁸, Siri Mjaaland², Silje W. Syversen⁹ and Guro L. Goll⁹, ¹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ²Norwegian Institute of Public Health, Section for Immunology, Oslo, Norway, Oslo, Norway, ³University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁴Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway, ⁵Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ⁶Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁷Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, ⁸Oslo University Hospital, Department of Immunology, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Health and Society, Oslo, Norway, Oslo, Norway
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapies have attenuated humoral vaccine responses and are prone to more severe infections. Assessing the persistence…
Abstract Number: 0962 • ACR Convergence 2024
Characterizing the Contribution of Myeloid Cells to Limited and Diffuse Cutaneous Systemic Sclerosis
Parker Jones¹, Salina Dominguez², Miranda Gurra³, Gaurav Gadhvi⁴, Tyler Therron², Kathleen Aren⁵, Carla Cuda³, Monique Hinchcliff⁶, Harris Perlman³, Hadijat Makinde³ and Deborah Winter⁷, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern University, Chicago, ³Northwestern University, Chicago, IL, ⁴University of Michigan, Ann Arbor, MI, ⁵Northwestern University Division of Rheumatology, Chicago, IL, ⁶Yale School of Medicine, Westport, CT, ⁷Northwestern University, Skokie, IL
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by multiorgan fibrosis. The two main subtypes are diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc…

« Previous Page
1
…
6
7
8
9
10
…
33
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].